Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART) [1]

Clinical Microbiology and Infection

Volumn 7, Issue 7, 2001, Pages 394-395

  Lopez Velez R ^a   Casado, J L ^a   Pintado, V ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

CELLULAR IMMUNITY; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; EPIDEMIC; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION SENSITIVITY; LETTER; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PARASITE EXAMINATION; PARASITE VIRULENCE; PRIORITY JOURNAL; RECURRENCE RISK; SPAIN; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION; VISCERAL LEISHMANIASIS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035410956     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1198-743X.2001.00270.x     Document Type: Letter

References (10)

1. Leishmania and human immunodeficiency virus coinfection: The first 10 years
2. Leishmania/HIV co-infection in southwestern Europe 1990-98
3. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
4. Clinico-epidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain
5. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals
6. Declining incidence and better outcome of visceral leishmaniasis in the era of HAART
7. Decreasing incidence of visceral leishmaniasis in HIV-infected patients after the introduction of HAART
8. Prospective evaluation and follow-up of european patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly avtive antiretroviral therapy
9. Relapsing visceral leishmaniasis in HIV-infected patients receiving successful protease inhibitor therapy
10. Visceral leishmaniasis relapses in HIV patients in spite of successful HARRT